NEW YORK — The US Food and Drug Administration on Wednesday released a SARS-CoV-2 reference panel to assist in the development and evaluation of diagnostic tests for the virus.
The FDA said the panel is an independent performance validation step for SARS-CoV-2 tests that are being used for clinical, not research, purposes. It is available to commercial and laboratory developers interacting with the FDA through the agency's pre-Emergency Use Authorization process.